scholarly journals Genetic Polymorphisms of CYP2C19 and Resistance to Clopidogrel Therapy among Iranian Patients Suffering from Ischemic Heart Disease

2016 ◽  
Vol 4 (3) ◽  
pp. 41-46 ◽  
Author(s):  
Behzad Poopak ◽  
Maed Heidari ◽  
Parviz Fallah ◽  
Nazila Safari ◽  
Saghar Rabieipoor ◽  
...  
2019 ◽  
Vol 16 (5) ◽  
pp. 379-386
Author(s):  
Nabila Akram ◽  
Ghulam Mustafa ◽  
Anum A Hanif ◽  
Shahzad Tawwab ◽  
Shabbir Hussain ◽  
...  

Aim: Polymorphisms in cytochrome P450 (CYP) 2C19 and paraoxonase-1 (PON-1) genes are thought to be involved in clopidogrel high on treatment reactivity in ischemic heart disease (IHD) patients. Methods: A total of 240 patients with IHD were screened for CYP2C19 loss-of-function alleles (LOF; *2, *3) and PON-1 Q192R. Patients were classified as responders and nonresponders to clopidogrel based upon platelet aggregation studies. Genotyping of the CYP2C19 and PON-1 allele was carried out by PCR-RFLP. Results: Results showed that 14.3% of the patients were nonresponders, whereas 85.7% were responders to the clopidogrel therapy. CYP2C19*3 allele showed significant association with clopidogrel high on treatment reactivity in IHD patients. Conclusion: Result of our study demonstrate that IHD patients with CYP2C19*3 allele can face the problem of clopidogrel high on treatment reactivity in Punjabi Pakistani population.


Author(s):  
Francesco Fedele ◽  
Mariateresa Pucci ◽  
Paolo Severino

1998 ◽  
Vol 21 (11) ◽  
pp. 831-836 ◽  
Author(s):  
S. Biggart ◽  
Mrcp, D. Chin ◽  
M. Fauchon ◽  
G. Cardew ◽  
L. Du Fou ◽  
...  

2014 ◽  
Vol 133 (5) ◽  
pp. 804-810 ◽  
Author(s):  
Cecilia Vecoli ◽  
Daniel Adlerstein ◽  
Erlet Shehi ◽  
Federico Bigazzi ◽  
Tiziana Sampietro ◽  
...  

2012 ◽  
Vol 223 (2) ◽  
pp. 409-415 ◽  
Author(s):  
Maria Grazia Andreassi ◽  
Daniel Adlerstein ◽  
Clara Carpeggiani ◽  
Erlet Shehi ◽  
Sonia Fantinato ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document